Ichthyosis, annular epidermolytic, 2
disease diseaseOn this page
Summary
Ichthyosis, annular epidermolytic, 2 (MONDO:0859574) is a disease caused by KRT1 (GenCC Strong), with 1 cohort gene.
At a glance
- Causal gene: KRT1 (GenCC Strong)
- Cohort genes: 1
- ClinVar variants: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ichthyosis, annular epidermolytic, 2 |
| Mondo ID | MONDO:0859574 |
| OMIM | 620148 |
| UMLS | C5774264 |
| MedGen | 1824037 |
| GARD | 0026747 |
| Is cancer (heuristic) | no |
Data availability: 3 ClinVar variants · 1 GenCC gene-disease record.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal dominant disease › autosomal dominant epidermolytic ichthyosis › annular epidermolytic ichthyosis › ichthyosis, annular epidermolytic, 2
Related subtypes (1): ichthyosis, annular epidermolytic 1
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
3 retrieved; paginated sample, class counts are floors:
2 pathogenic/likely pathogenic, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 15911 | NM_006121.4(KRT1):c.1436T>C (p.Ile479Thr) | KRT1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 15912 | NM_006121.4(KRT1):c.1435A>T (p.Ile479Phe) | KRT1 | Pathogenic | no assertion criteria provided |
| 66650 | NM_006121.4(KRT1):c.563A>G (p.Asn188Ser) | KRT1 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 18 · Orphanet: 8 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| KRT1 | Definitive | Autosomal dominant | annular epidermolytic ichthyosis | 18 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| KRT1 | Orphanet:2199 | Epidermolytic palmoplantar keratoderma |
| KRT1 | Orphanet:281139 | Annular epidermolytic ichthyosis |
| KRT1 | Orphanet:281190 | Congenital reticular ichthyosiform erythroderma |
| KRT1 | Orphanet:312 | Autosomal dominant epidermolytic ichthyosis |
| KRT1 | Orphanet:50942 | Striate palmoplantar keratoderma |
| KRT1 | Orphanet:530838 | KRT1-related diffuse nonepidermolytic keratoderma |
| KRT1 | Orphanet:538574 | Palmoplantar keratoderma-hereditary motor and sensory neuropathy syndrome |
| KRT1 | Orphanet:79503 | Ichthyosis hystrix of Curth-Macklin |
Cohort genes → proteins
1 cohort genes, 1 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 1 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| KRT1 | HGNC:6412 | ENSG00000167768 | P04264 | Keratin, type II cytoskeletal 1 | gencc,clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| KRT1 | Keratin, type II cytoskeletal 1 | May regulate the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein C kinase 1 (RACK1). |
Protein-family classification
Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Other/Unknown | 1 | 1.8× | 0.558 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| KRT1 | Other/Unknown | no | Keratin_II, IF_conserved, Keratin_2_head |
Expression context
Cohort genes with no expression data: 0.
1 cohort gene are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 1 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| mammalian vulva | 1 |
| skin of hip | 1 |
| upper leg skin | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| KRT1 | 177 | tissue_specific | marker | mammalian vulva, upper leg skin, skin of hip |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| KRT1 | 2,716 |
Structural data
PDB: 1 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| KRT1 | P04264 | 3 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 10. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| Regulation of FXIIa and plasma kallikrein activity | 1 | 1142.0× | 0.009 | KRT1 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | 1 | 278.5× | 0.014 | KRT1 |
| Developmental Cell Lineages | 1 | 223.9× | 0.014 | KRT1 |
| FXIIa activates plasma kallikrein-kinin system | 1 | 173.0× | 0.014 | KRT1 |
| Formation of the cornified envelope | 1 | 87.8× | 0.023 | KRT1 |
| Keratinization | 1 | 55.7× | 0.030 | KRT1 |
| Innate Immune System | 1 | 25.5× | 0.054 | KRT1 |
| Neutrophil degranulation | 1 | 23.1× | 0.054 | KRT1 |
| Developmental Biology | 1 | 14.5× | 0.077 | KRT1 |
| Immune System | 1 | 13.0× | 0.077 | KRT1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| complement activation, lectin pathway | 1 | 1685.2× | 0.003 | KRT1 |
| protein heterotetramerization | 1 | 1053.2× | 0.003 | KRT1 |
| cornification | 1 | 1053.2× | 0.003 | KRT1 |
| fibrinolysis | 1 | 842.6× | 0.003 | KRT1 |
| establishment of skin barrier | 1 | 455.5× | 0.004 | KRT1 |
| regulation of angiogenesis | 1 | 421.3× | 0.004 | KRT1 |
| intermediate filament organization | 1 | 240.7× | 0.005 | KRT1 |
| keratinization | 1 | 234.1× | 0.005 | KRT1 |
| negative regulation of inflammatory response | 1 | 137.0× | 0.008 | KRT1 |
| response to oxidative stress | 1 | 130.6× | 0.008 | KRT1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1
Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| KRT1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 1 | KRT1 |
Undrugged target profiles
1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| KRT1 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
- Cohort genes: KRT1